18 results about "STD - Sexually transmitted disease" patented technology

The present application belongs to the technical field of Dioscorea alata Blume anthracnose prevention and treatment, and particularly relates to application of a biological agent material for enhancing expression of DaMYB48 in resisting anthracnose. The application of the biological agent material for enhancing expression of DaMYB48 in resisting anthracnose is characterized in that the nucleotide sequence of DaMYB48 is shown as SEQ ID NO. 3. The expression of DaMYB48 is enhanced to enhance the resistance of the plant to anthracnose. The application of the agent for enhancing expression of DaMYB48 in resisting anthracnose of Dioscorea alata Blume can significantly enhance the resistance of the plant to anthracnose, and the area of the disease spot is significantly reduced, and the prevention and treatment effect is stable. The material used in the present application is a biological material, and will not pollute the environment. On the other hand, the present application reduces the invasion of anthracnose by regulating the closure of stomata of leaves, belongs to physical action, and thus will not cause the anthracnose pathogen to produce drug resistance.

There is provided a compound having the structure of formula (R-l): LG-RG-LRM-MOI, or a salt thereof, where: LG is a group comprising a target binding moiety that binds to Bentuximab or a biosimilar analog thereof, LRM is a linking group comprising formula (I); and MOI is a moiety of interest that includes monomethyl aurestatin D (MMAD), monomethyl aurestatin E (MMAE), or monomethyl aurestatin F (MMAF). Also provided are a conjugate, a compound having the structure of formula (R-l) and bentuximab or a biologically similar analog thereof, and methods of using the conjugate and the compound to treat various cancerous conditions. (I)

The invention belongs to the technical field of poultry disease detection, and particularly relates to a poultry immunosuppressive disease joint detection method based on multiple fluorescent quantitative PCR (Polymerase Chain Reaction). The method sequentially comprises the following steps: determining a detection target, designing a specific primer and a probe, preparing a positive standard substance, pre-treating a sample, extracting nucleic acid, purifying a nucleic acid sample, establishing a multiple fluorescent quantitative PCR reaction system, setting a multiple fluorescent quantitative PCR reaction program, amplifying, and analyzing and judging a result. On the basis, by designing a multiplex fluorescent quantitative PCR detection system and the specific primer probe, the kit has the advantages that synchronous detection of multiple poultry immunosuppressive pathogens is realized, multiple independent detection on the same sample is not needed, the operation process is simplified, the detection cost is reduced, and the waste of the sample is reduced; the problems that a traditional single pathogen detection method is low in efficiency and high in cost are solved.

The invention concerns an immunomodulatory complex comprising a Tat polypeptide of SEQ ID NO: 1 or a variant thereof which binds heparan sulfate, linked to a ligand of an antigen-presenting cell, NK or NKT cell surface receptor other than a sulfated sugar of the glycosaminoglycan family, with the proviso that the immunomodulatory complex lacks the peptide Tat 49-57 (RKKRRQRRR), and its use in immunotherapy of cancer, infectious, immunoinflammatory or autoimmune diseases.

Cathepsin D peptides are provided that are capable of interacting with and / or inhibiting the formation of beta amyloid aggregates, thereby leading to a competitive reduction of amyloid- amyloid interactions. Also provided are recombinant expression vectors encoding said peptides as well as of pharmaceutical formulations comprising said peptide-analogues. Said peptides, compositions and recombinant vectors are useful as therapeutic agents in the treatment and / or amelioration of the symptoms of amyloidoses such as Alzheimer's disease.

The present application relates to CTLA-4 variant immunomodulatory proteins and uses thereof. Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for the treatment of autoimmune or inflammatory conditions. Compositions and methods of making and using such proteins are provided.

The present invention relates to the field of genetically engineered drugs, and particularly relates to a human interleukin 10-Fc fusion protein, its encoding gene and applications. The present invention provides an IL10-Fc fusion protein, wherein the C-terminus of IL-10 is directly or via a linker peptide linked to the N-terminus of the Fc protein of human IgG2 or human IgG4. The present invention also discloses a method for using the IL10-Fc fusion protein drug for treating diseases, the method comprising administering a therapeutically effective amount of the drug to an individual suffering from a disease, and the diseases include inflammatory conditions, immune-related disorders, fibrotic disorders and cancers, etc.

The present invention provides a method for treating an inflammatory condition of an eye of a subject, the method comprising administering to the subject an effective amount of a conjugate comprising an IGF-1R ligand, or a portion or variant thereof, and a disease alleviator.

The present disclosure describes glucocorticoid agonist compounds, conjugates thereof with binding proteins, pharmaceutical compositions thereof, and methods and uses for treating a disease or condition, such as an autoimmune condition or an inflammatory condition. # imgabs0 #

The invention relates to a medical training model, in particular to a mammary gland ultrasound examination guided puncture simulation training model, comprising: a bionic matrix module which is formed by sequentially stacking two layers of gelatin, the concentration of the gelatin solution of each layer being different, and respectively simulating a fat layer and a gland layer; the focus simulation module comprises a cystic focus simulation unit and a real disease simulation unit; wherein the cystic focus simulation unit adopts a liquid or semi-flow medium, namely simulated human body liquid; wherein the solid lesion unit adopts a biological tissue block or a high-density gel block which is a biological tissue for simulating solid lesion; the focus simulation module is mixed in a gelatin solution before gelatin is solidified when a gland layer is simulated, and the focus simulation module is wrapped and fixed after the gelatin solution is solidified. The method has the advantages that a gradient bionic structure is simulated according to needs, 'image-hand feeling 'integrated focus simulation can be achieved, the cost is low, and the performance is high.

Provided herein are compounds of formula (I) that modulate PlKfyve and methods of using the compounds in PlKfyve-associated disorders, such as fibro-inflammatory conditions (e.g., interstitial lung disease, or a liver, kidney, cardiac, or systemic fibrotic condition).

This invention relates to the field of pig selective breeding technology, and particularly to a SNP molecular marker, primers, and applications related to the IFITM1 gene and inter-sex disease in pigs. The nucleotide sequence of this molecular marker is SEQ ID NO:1, and the 32nd base Y in the nucleotide sequence of the SNP molecular marker is a polymorphic site. At this polymorphic site, individuals with genotypes TT and TC exhibit inter-sex disease characteristics, while individuals with genotype CC do not exhibit inter-sex disease characteristics. The SNP molecular marker is located in the second exon of the IFITM1 gene on pig chromosome 2. This SNP molecular marker is closely related to the inter-sex disease trait in pigs. By detecting the SNP site using the primers disclosed in this invention, individuals carrying the pathogenic gene can be screened for use in breeding selection of pigs to prevent the spread of inter-sex diseases in pigs.

This disclosure provides a method for treating a subject with cancer or light chain amyloidosis, the method comprising administering to the subject a combination therapy containing an effective amount of nirostat dihydrobromide form A and B cell maturation antigen (BCMA) targeted therapy and providing the use of the combination therapy.

The present disclosure relates to a method for detecting and distinguishing between Treponema pallidum subspecies in a samples and distinguishing between venereal syphilis and non-venereal disease (e.g., yaws or bejel). Compositions, assays, and kits for use in the methods are also disclosed.

The invention relates to an inducing method and system of a systemic amyloid degeneration mouse model, and relates to the technical field of biomedical models, amyloid substances extracted from diseased tissues are injected into a standard strain laboratory mouse as an inducing medium, and the disease progress is controlled by regulating and controlling parameters such as injection dosage and frequency. The method successfully overcomes the defects that an existing model depends on scarce lines or genetic modification, the disease is unstable, and the deposition range is limited, typical amyloid protein deposition can be stably and repeatedly induced in multiple organs of the whole body, and the severity of the disease can be flexibly regulated and controlled according to research requirements. An ideal animal model tool which is low in cost, reliable in phenotype and convenient to popularize is provided for disease mechanism research and drug research and development.

The present invention discloses a traditional Chinese medicine directional transdermal instrument, which comprises a box body, a liquid medicine placer and a soaking container. A waste liquid collection device is arranged at the bottom inside the box body. Placing plates are fixed on the opposite side walls inside the box body. A double-headed pump is installed on one side of the upper end of the placing plate. A delivery pipe is connected to the double-headed pump. A four-way valve is arranged inside the box body. One end of the delivery pipe is connected to the four-way valve. A waste liquid collector is installed on the placing plate. The present invention achieves the purpose of soaking the private parts of male patients with traditional Chinese medicine, promotes blood circulation, activates cells, accelerates the excretion of waste and harmful substances in cells, effectively eliminates bacteria, thereby protecting the prostate of men, reducing the occurrence of prostate diseases. When treating male venereal diseases, the role of the liquid medicine can be fully exerted, and directional and precise drug delivery promotes the full and rapid absorption of the liquid medicine, directly reaches the focus, quickly solves the embarrassing problems of patients, and improves the treatment effect.

The invention relates to the technical field of antiviral drugs, and particularly discloses a combined preparation for treating lung diseases caused by respiratory virus infection. The combined preparation provided by the invention is prepared from the following raw materials in parts by weight: 5-7 parts of pinellia ternate, 5-7 parts of adenophora stricta, 5-7 parts of fritillaria, 5-8 parts of pericarpium citri reticulatae, 5-8 parts of radix ophiopogonis, 5-7 parts of almond, 4-7 parts of liquorice, 4-5 parts of siegesbeckia orientalis and 3-7 parts of patrinia scaniosaefolia. The combined preparation is suitable for various heat diseases such as pneumonia, influenza and the like and the initial stage of tuberculosis. Meanwhile, the combined preparation does not damage normal cells, and can inhibit downstream inflammation (IL-1beta, IL-6 and TNF-alpha) induced by IL-1beta and pulmonary fibrosis (MMP-1 and alpha-SMA) related signal conduction, so that the phenomenon of inhibiting lung cell growth caused by IL-1beta is avoided, and the effect of repairing lung tissues is achieved.